Fundraising FoxCirius Therapeutics
Grand Rapids, US · Founded 2015 · Delaware corporation · 3 known investors
Find your way into Cirius Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
236 people can intro you to Brian
Ask Bob Baltera to introduce you to Brian Farmer
You →Bob · together at Laguna Pharmaceuticals →Brian
Sign up to find every way you can get introduced to Cirius Therapeutics
- Your email: who you already know at Cirius Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cirius Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with chronic metabolic diseases driven by insulin resistance, including Type 2 Diabetes and obesity.
Founders & leadership
JC
Jerry CallahanExecutive
BF
RB
Robert BalteraExecutive
HD
Howard DittrichExecutive
Board
MJ
Michael JandernoaBoard director
MO
Mark OlesnavageBoard director
DV
David Van AndelBoard director
NK
Nilesh KumarBoard director
DE
RZ
Robert ZerbeBoard director
Investors · 3
Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto
How we know: Frazier Life Sciences's portfolio page · board seat on SEC Form D · Not right? Tell us
Frazier Healthcare PartnersreportedSeattle · $50M – $400M
How we know: funding news · Not right? Tell us
Novo HoldingsreportedCopenhagen · $1.1M – $54M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$49.6M disclosed across 6 rounds · 2017–2025
▶$800KraisedOct 2025 · 22 investors · BiotechnologyRule 506(b)
▶$800KraisedOct 2025 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael JandernoaDirector
- Robert A BeardsleyExecutive Officer
- Robert ZerbeDirector
- David Van AndelDirector
- Jerry CallahanExecutive Officer
- Offering amount
- $1.2M
- Amount sold
- $800K
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedOct 2024 · 22 investors · BiotechnologyRule 506(b)
▶$1MraisedOct 2024 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David Van AndelDirector
- Michael JandernoaDirector
- Mark OlesnavageExecutive Officer
- Robert BeardsleyExecutive Officer
- Jerry CallahanExecutive Officer
- Robert ZerbeDirector
- Offering amount
- $1.6M
- Amount sold
- $1M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedAug 2024 · 24 investors · BiotechnologyRule 506(b)
▶$1.3MraisedAug 2024 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael JandernoaDirector
- Jerry CallahanExecutive Officer
- Mark OlesnavageExecutive Officer
- David Van AndelDirector
- Robert ZerbeDirector
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedMay 2019 · 29 investors · Other Health CareRule 506(b)
▶$7.5MraisedMay 2019 · 29 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Elaine SunDirector
- Baltera BobExecutive Officer, Director
- Daniel Estes, Ph.D.Director
- Michael JandernoaDirector
- Nilesh Kumar, Ph.D.Director
- David Van AndelDirector
- Robert Zerbe, M.D.Director
- Dennis Fenton, Ph.D.Director
- Brian FarmerExecutive Officer
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$9MraisedAug 2018 · 30 investors · Other Health CareRule 506(b)
▶$9MraisedAug 2018 · 30 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Nilesh Kumar, Ph.D.Director
- Baltera BobExecutive Officer, Director
- Robert Zerbe, M.D.Director
- Brian FarmerExecutive Officer
- David Van AndelDirector
- Michael JandernoaDirector
- Dennis Fenton, Ph.D.Director
- Daniel Estes, Ph.D.Director
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$30MraisedApr 2017 · 21 investors · BiotechnologyRule 506(b)
▶$30MraisedApr 2017 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian FarmerExecutive Officer
- Nilesh KumarDirector
- Robert BalteraExecutive Officer, Director
- David Van AndelDirector
- Howard DittrichExecutive Officer
- Daniel EstesDirector
- Michael JandernoaDirector
- Robert ZerbeDirector
- Offering amount
- $40.5M
- Amount sold
- $30M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Amicus TherapeuticsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
SitryxSitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism. It has entered a global licensing and research collaboration with Eli Lilly and Company.
Nurix TherapeuticsNurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
Cyrus BiotechnologyCyrus operates a protein engineering platform that combines AI and Rosetta computational design methods with a biochemistry lab performing large-scale deep mutagenesis scanning, protein stabilization, immunogenicity reduction, and affinity/specificity tuning. It designs and re-engineers biologic therapeutics, working on internal and partnered drug programs including COVID assets and gene therapy candidates.
Companies working in the same space as Cirius Therapeutics.
In the news
Frequently asked questions
- What does Cirius Therapeutics do?
- Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with chronic metabolic diseases driven by insulin resistance, including Type 2 Diabetes and obesity.
- Who are Cirius Therapeutics's investors?
- Cirius Therapeutics's investors include Frazier Life Sciences, Frazier Healthcare Partners, Novo Holdings.
- How much funding has Cirius Therapeutics raised?
- Cirius Therapeutics has disclosed $49.6M raised across 6 rounds.
- Where is Cirius Therapeutics headquartered?
- Cirius Therapeutics is headquartered in Grand Rapids, US.